Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19287152 | 0.83 | MAPT (0.78) | MAPTMEN1KMT2ATSHRNOTUM | |
| SCHEMBL25517743 | 0.81 | NOTUM (0.60) | MAPTMEN1KMT2ATSHRNOTUM | |
| SCHEMBL25428603 | 0.79 | TSHR (0.49) | MAPTMEN1KMT2ATSHRNOTUM | |
| SCHEMBL23833982 | 0.76 | ALDH1A1 (0.49) | MAPTMEN1KMT2ATSHRNOTUM | |
| Hydrochloric Acid SCHEMBL23834039 | 0.75 | ALDH1A1 (0.48) | MAPTMEN1KMT2ATSHRNOTUM | |
| Hydrochloric Acid SCHEMBL23833985 | 0.75 | ALDH1A1 (0.48) | MAPTMEN1KMT2ATSHRNOTUM | |
| SCHEMBL25428357 | 0.74 | ALDH1A1 (0.47) | MAPTMEN1KMT2ATSHRNOTUM | |
| Hydrochloric Acid SCHEMBL23833979 | 0.74 | ALDH1A1 (0.47) | MAPTMEN1KMT2ATSHRNOTUM | |
| SCHEMBL23849032 | 0.73 | NOTUM (0.48) | MAPTMEN1KMT2ATSHRNOTUM | |
| SCHEMBL25508267 | 0.72 | NOTUM (0.47) | MAPTMEN1KMT2ATSHRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | MAPT 3302/4885MEN1 3555/4885KMT2A 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.